Lasmiditan efficacy in migraine attacks with mild vs. moderate or severe pain.

Mario Fernando Prieto PeresRaghavendra VasudevaSimin K BayganiEllen B DennehyMaurice Borges VincentDeborah I Friedman

Published in: Current medical research and opinion (2021)

Data from two placebo-controlled, single-attack trials, and an open-label study including treatment of multiple attacks, suggested a tendency to relatively better efficacy outcomes when LTN treatment was initiated at mild vs. moderate to severe pain. Further research is needed to better understand the relationship of lasmiditan outcomes to the time of administration in the course of a migraine attack.

Keyphrases

chronic pain
pain management
early onset
high intensity
type diabetes
placebo controlled
machine learning
radiation therapy
double blind
study protocol
artificial intelligence
insulin resistance
smoking cessation